<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433445</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589X2106</org_study_id>
    <secondary_id>2011-000861-10</secondary_id>
    <nct_id>NCT01433445</nct_id>
  </id_info>
  <brief_title>Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis</brief_title>
  <official_title>A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess safety as well as establish a Recommended Phase II dose of the&#xD;
      combination of panobinostat and ruxolitinib in patients with or without the JAK2V617F&#xD;
      mutation who have been diagnosed with primary myelofibrosis (PMF), Post Essential&#xD;
      Thrombocythemia Myelofibrosis (PET MF), or Post-Polycythemia Vera Myelofibrosis (PPV MF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2011 the treatment goals for MF focused on symptom-orientated palliation and quality of&#xD;
      life. Both ruxolitinib and panobinostat, as single agents, had shown significant improvement&#xD;
      in both of those treatment goals and ruxolitinib had also shown greater reductions in&#xD;
      splenomegaly compared to the standard of care at that time. To further the benefit seen with&#xD;
      ruxolitinib in MF patients, panobinostat was added to the treatment regimen to act&#xD;
      synergistically in the blockade of the dysregulated pathway driving this disease.&#xD;
&#xD;
      The study was conducted in 2 phases - an escalation phase and an expansion phase.&#xD;
&#xD;
      Escalation phase: the study utilised the Bayesian Logistic Regression Model (BLRM),&#xD;
      incorporating escalation with overdose control (EWOC), which is a well established method for&#xD;
      dose escalation in oncology trials. Following this process, successive cohorts of 3 newly&#xD;
      enrolled patients received increasing doses of ruxolitinib and panobinostat until the maximum&#xD;
      tolerated dose (MTD) or recommended phase II dose (RPIID) was determined. Once the MTD and/or&#xD;
      RPIID were suspected in a minimum of 3 patients, additional patients were enrolled to the&#xD;
      same cohort level to reach a minimum of 9 evaluable patients. The process also included&#xD;
      safety, PK/PD assessments and estimates of efficacy based on measures of splenic reduction at&#xD;
      each dose level.&#xD;
&#xD;
      Expansion: following the determination of the MTD and/or RPIID, a dose expansion phase was&#xD;
      conducted at that dose to further define the safety and tolerability of the combination. At&#xD;
      least 13, and no more than 23, additional patients were to be enrolled into the expansion&#xD;
      phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2011</start_date>
  <completion_date type="Actual">June 22, 2020</completion_date>
  <primary_completion_date type="Actual">June 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of dose limiting toxicities at the different dose levels</measure>
    <time_frame>Cycle 1 (a cycle = 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events, serious adverse events, notable laboratory, vital signs and ECG results by dose level</measure>
    <time_frame>From screening until safety follow up visit (30 days after last treatment), approx. 8.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of ruxolitinib and panobinostat at various dose levels</measure>
    <time_frame>Ruxolitinib on days 1,2 and 6; Panobinostat on days 2-3 and days 6-7</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ruxolitinib and panobinostat at various dose levels</measure>
    <time_frame>Ruxolitinib on days 1,2 and 6; Panobinostat on days 2-3 and days 6-7</time_frame>
    <description>Cmax is the Peak Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ruxolitinib and panobinostat at various dose levels</measure>
    <time_frame>Ruxolitinib on days 1,2 and 6; Panobinostat on days 2-3 and days 6-7</time_frame>
    <description>Tmax: The time of maximum observed concentration sampled during a dosing interval.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Idiopathic Myelofibrosis</condition>
  <condition>Post Essential Thrombocythemia Myelofibrosis</condition>
  <condition>Post Polycythemia-Vera Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ruxolitinib 5 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ruxolitinib 10 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 15 mg three times per week (TIW) every other week (QOW) on a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 20 mg three times per week (TIW) every other week (QOW) on a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6/6+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 25 mg three times per week (TIW) every other week (QOW) on a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panobinostat</intervention_name>
    <description>Given 3 times a week, every other week in 28-day cycles.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6/6+</arm_group_label>
    <other_name>LBH589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ruxolitinib</intervention_name>
    <description>Given twice daily in 28-day cycles.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6/6+</arm_group_label>
    <other_name>INC424</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of myelofibrosis, either PMF, PPV or PET MF&#xD;
&#xD;
          -  Palpable splenomegaly ≥ 5cm&#xD;
&#xD;
          -  May have been previously treated with either panobinostat or ruxolitinib (unless&#xD;
             discontinued for clinically relevant toxicities)&#xD;
&#xD;
          -  Acceptable lab ranges for all organ systems&#xD;
&#xD;
          -  Specifically: Platelet count &gt; 100,000 not reached with the aide of transfusions&#xD;
&#xD;
          -  Blast count &lt; 10% at screening&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  Must be able to discontinue all drugs being used to treat MF at least 7 days prior to&#xD;
             starting study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Clinically significant heart disease&#xD;
&#xD;
          -  Splenic irradiation within 12 months of starting study drug&#xD;
&#xD;
          -  Need for ongoing systemic anticoagulation with the exception of Aspirin &lt; 150mg/day or&#xD;
             Low Molecular Weight Heparin&#xD;
&#xD;
          -  History of platelet dysfunction or bleeding disorder in the 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Patient is at risk for spontaneous bleeding&#xD;
&#xD;
          -  Willing and/or eligible for stem-cell transplantation&#xD;
&#xD;
          -  Impairment of gastro-intestinal function that may impact the absorption of study&#xD;
             treatment&#xD;
&#xD;
          -  Unwilling to use highly effective methods of contraception during dosing and for 13&#xD;
             weeks (female participants) or for 6 months (male participants and their female&#xD;
             partners) after stopping study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17838</url>
    <description>Novartis Clinical Trials results database</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis</keyword>
  <keyword>Panobinostat</keyword>
  <keyword>LBH589</keyword>
  <keyword>Ruxolitinib</keyword>
  <keyword>MF</keyword>
  <keyword>PMF</keyword>
  <keyword>PPV</keyword>
  <keyword>PPV-MF</keyword>
  <keyword>PET</keyword>
  <keyword>PET-MF</keyword>
  <keyword>JAK2</keyword>
  <keyword>DACi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

